Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
TD Cowen 4th Annual Oncology Innovation Summit on
Tuesday, May 30, 2023at 8:30 AM ET(virtual)
Jefferies Healthcare Conferenceon Thursday, June 8, 2023at 2:30 PM ETin New York, NY
A live webcast of both events will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in